Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)

References

• Gómez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16:2352–2358.
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:3041–3050.
   PubMed Web of Science ®Google Scholar
• Gómez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998;16:2065–2069.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol. 1996;14:1957–1960.
   PubMed Web of Science ®Google Scholar
• Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18:3558–3585.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Weller EA, Habermann TM, et al. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2007;225:443s. (Abstract 8011)
   Google Scholar
• Cox DR. Analysis of binary data. London: Methuen and Co; 1970.
   Google Scholar
• Peto R, Pike MC, Armitage NE, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Analysis and examples. Br J Cancer. 1977;35:1–39.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;34:181–220.
   Google Scholar
• Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood. 1997;89:3974–3979.
   PubMed Web of Science ®Google Scholar
• Björkholm M, Ösby E, Hagberg H, et al. Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin’s lymphoma [abstract 2655]. Blood. 1999;94:599a.
   Google Scholar
• Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin’s lymphoma treated with combination chemotherapy. Ann Oncol. 1994;5:127–132.
   PubMed Web of Science ®Google Scholar
• Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL) ). Ann Oncol. 1994;5:895–900.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma. Oncology (Williston Park, N.Y.). 2003;17:21–26.
   PubMedGoogle Scholar
• Ösby E, Hagberg H, Kvaløy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101:3840–3848.
   PubMed Web of Science ®Google Scholar
• Burton C, Linch D, Hoskin P, et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer. 2006;94:806–813.
   PubMed Web of Science ®Google Scholar
• Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87:277–283.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Bosly A, et al. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87:429–430.
   PubMed Web of Science ®Google Scholar
• Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014;165:489–496.
   PubMed Web of Science ®Google Scholar
• Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup study (ECOG 4494, CALGB 9793): Consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010;151:143–151.
   PubMed Web of Science ®Google Scholar
• Hirakawa T, Yamaguchi H, Yokose N, et al. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 2010;89:897–904.
   PubMed Web of Science ®Google Scholar
• Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology group experience. J Clin Oncol. 1986;4:295–305.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Silvestre AS, Rossi FG, et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk. 2012;12:297–305.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Johnson HE, Lugtenburg PJ, et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer. 2012;20:647–652.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16:1299–1309.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy . Leuk Lymphoma. 2003;44:2069–2076.
   PubMed Web of Science ®Google Scholar
• Salar A, Haioun C, Rossi FG, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res. 2012;36:548–553.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:187–1826.
   Web of Science ®Google Scholar
• Lee L, Crump M, Khor S, et al. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol. 2012;158:481–488.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterberg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. German high-grade non-Hodgkin study group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Park S, Kang CI, Chung DR, et al. Clinical significance of non-neutropenic fever in the management of diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Comparison with febrile neutropenia and risk factor analysis. Cancer Res Treat. 2015;47:448–457.
   PubMedGoogle Scholar
• Choi YW, Jeong SH, Ahn MS, et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci. 2014;29:1493–1500.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymph. 2001;2:47–56.
   PubMedGoogle Scholar
• Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;37:351–360.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88:181–186.
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–237.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Bosly A, Szucs TD, et al. Impact of neutropenia in chemotherapy-European study group. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU prospective observational European neutropenia study. Br J Haematol. 2009;144:677–685.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90:190–199.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology [Internet]. 2015. Available from: http://www.nccn.org/index.asp.
   Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24:2475–2484.
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International lymphoma study group classification of non-Hodgkin’s lymphoma: the non-Hodgkin’s lymphoma classification project. 1997;89:3909–3918.
   Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–3167.
   PubMed Web of Science ®Google Scholar
• Chan KKW, Siu E, Krahn MD, et al. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol. 2012;30:1064–1071.
   PubMed Web of Science ®Google Scholar
• Lathia N, Isogai PK, De Angelis C, et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst. 2013;105:1078–1085.
   PubMedGoogle Scholar
• Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116:5103–5110.
   PubMed Web of Science ®Google Scholar
• Carson KR, Riedell P, Lynch R, et al. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol. 2015;6:211–218.
   PubMed Web of Science ®Google Scholar
• Nolasco-Medina D, Reynoso-Noveron N, Mohar-Betancourt A, et al. Comparison of three chemotherapy regimens in eldery patients with diffuse large B-cell lymphoma: experience at a single national reference center in Mexico. Biomed Res Int. 2016:9817606. doi: 10.1155/2016/9817606.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460–468.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Chung JS, Song MK, et al. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2012;69:1165–1172.
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Nakasone H, Akahoshi Y, et al. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patient with non-Hodgkin lymphoma. J Chemother. 2015;27:99–105.
   PubMed Web of Science ®Google Scholar
• Meguro A, Ozaki K, Sato K, et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma. 2012;53:43–49.
   PubMed Web of Science ®Google Scholar